Abstract:From May 2003, 13 patients with refractory hematological malignancies received HLA haploidentical hematopoietic stem cell transplantations in out BMT center. 13 patients, including 9 male and 4 female, are with an average age of 31.4 years (range, 15 to 46). Among them, 4 cases were of accelerated phase of CML, 1 blast phase of CML, 1 polyleptic ANLL-M3, 1 ANLL-M2, 2 ANLL M4, 1 ANLL M6, 2 NHL, and 1 MDS-RA. Of the 13 donors, 8 were the mothers of the recipients, 4 were the siblings, and the rest was the son. All the donors were HLA haploidentical matched to the patients. 4 patients were conditioned with CY/TBI/Ara-C regimen, (Ara-C 3. 0g/m 2 , q12h, ×3 d; CTX45 mg/kg×2 d; TBI 5 Gy ×2 d, ATG5 mg/kg ×4 d)). 8 patients were conditioned with improved BU/CY regimen, (BU 4 mg/kg ×3 d, CTX 1. 8 g/m 2 ×2 d, Ara-C 2 g/m 2 × 1 d, Me-CCNU 250 mg/m 2 ×1 d, ATG5 mg/kg ×4 d) and 1 patient of MDS-RA was conditioned with nonmyeloablative regimen (Fludarabine 30 mg/m 2 /d × 5d, CTX 30 mg/kg/d x 2d, TBI 300 cGy d1. G-CSF was given to the donors at 250 mg /day for a continuous 5~7 days. On the 4th~8th day, their bone marrow was collected under epidural anesthesia. In the simple bone marrow transplantation, the amount of the bone marrow collected was 15~20 ml/kg recipient b.w. And BMT associated with HSCT was given to 9 of the patients. The average parameter of the mononuclear cells re-infused was 8.84×10 8 /kg; while the CD34 + cells was 2.67×10 6 /kg. The treatments of CsA, MTX, MMF, ATG, and anti-CD25 monoclonal antibody were given as prophylaxis for GVHD. All the 13 patients received standard supportive care, and got hematopoietic reconstitution. The mean time of engraftment with neutrophil count more than 1.0 x 10 9 /L was 15 days and platelet count more than 20 x 10 9 /L was 21 days. All the patients was tested with STR-PCR, and showed a genotype the same as the donor’s. 5 of the 13 patients suffered grade I~II acute GVHD. 1 patient suffered grade III dermo-GVHD 30 days after transplantation. The CMV-DNA of 3 patients turned out positive after the transplantation, 2 patients suffered grade I~II hemorrhagic cystitis. There were totally 2 deaths, one of which who was in the IV phase of NHL died due to recurrent disease after the transplantation, the other suffered graft rejection on the 28 day of the hematopoietic reconstitution, which complicated with centrum infection after the second transplantation. 11 recipients got CR after transplantation. 1 patient of the accelerated phase of CML relapsed on the +70 day and 1 M3 patient relapsed 18 months after transplantation, both of them died after ineffective therapy. One patient of accelerated phase of CML relapsed genetically 1 year after the transplantation, and then got remission after the administration of Glivec. Full donor-type engraftment was sustained successfully in these 8 recipients. The patients were followed up until June 2005, with a median follow-up time of 18 months (range, 12 to 25 months). Our initial results show that the conditioning regimens, either with or without radiotherapy, are able to transplant the haploidentical hematopoietic stem cell without first T lymphocytes depletion. If ATG, mycophenolate mofetil and anti-CD25 monoclonal antibody, etc. are applied, the incidence of severe aGVHD will be decreased. 8 of the 13 patients survived for more than one year after transplantation. It shows favorable short-term curative effects.

[Mismatched Hematopoietic Stem Cell Transplantation Using GIAC Protocol: Report of 100 Cases].

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

[A Novel Approach to HLA-mismatched Transplantation].

Haploidentical Hematopoietic Cell Transplantation (HCT) Compared with Matched HCT from Family Donors: Report of 216 Cases.

A Novel Approach to Human Leukocyte Antigen-Mismatched Transplantation in Patients with Malignant Hematological Disease

Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation

[Human Leukocyte Antigen Mismatched Hemopietic Stem Cell Transplants for the Treatment of Leukemia].

Transplantation of HLA-Mismatched Stem Cell Transplantation Without T Cell Depletion for the Treatment of Malignant Hematological Disease.

Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China

Clinical Study on Haploid HLA-haploidentical Hematopoietic Stem Cell Transplantation for Treatment of Malignant Hematological Disease

Treatment Of Acute Leukaemia With Unmanipulated Hla-Mis-Matched/Haploidentical Blood And Bone Marrow Transplantation

HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

Haploidentical, Unmanipulated G-CSF-primed Peripheral Blood Stem Cell Transplantation for High-Risk Hematologic Malignancies: an Update.

Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

Related HLA-mismatched/haploidentical Hematopoietic Stem Cell Transplantation Without in Vitro T-cell Depletion: Observations of a Single Chinese Center.

Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion

The Overview of the Short Term Curative Effects of HLA Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

The Clinical Study of Non-T-depleted Human Leukocyte Antigen Mismatched Hematopoietic Stem Cell Transplants with Total Body Irradiation for the Treatment of Leukemia

Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin

Clinical Study of G-CSF Mobilized Allogeneic Bone Marrow Cells Plus Peripheral Blood Stem Cells Transplantation for Hematological Diseases

Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy